The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in…
The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in…